Bayer Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Bayer
Unlock Strategic Clarity
Bayer’s BCG Matrix preview highlights how its diverse portfolio—pharmaceuticals, crop science, and consumer health—align across Stars, Cash Cows, Question Marks, and Dogs, revealing where growth potential and cash generation intersect with strategic risk. This snapshot shows which divisions drive market share and which may need divestment or reinvention. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Nubeqa Prostate Cancer Treatment
Nubeqa (darolutamide) reached blockbuster status with global sales above 1.5 billion euros by end-2025, growing >75% year-on-year and driving Pharmaceuticals segment revenue growth.
It’s rapidly gaining share as a leading androgen receptor inhibitor for metastatic hormone-sensitive prostate cancer and is a primary growth engine for Bayer.
A third regulatory approval in China is expected in 2026; Bayer is investing heavily in promotion to cement Nubeqa as a standard of care.
Kerendia for Chronic Kidney Disease
Kerendia for Chronic Kidney Disease is a Stars asset: sales surged nearly 87% in 2025 to about EUR 1.1 billion, driven by clear impact in type 2 diabetes patients with kidney disease.
The product is expanding via new indications, including 2025 priority reviews for heart failure, widening addressable market to ~45 million high-risk patients globally.
By end-2025 Kerendia plus Nubeqa formed Bayer’s pharma recovery backbone, contributing roughly EUR 2.3 billion combined sales; continued investment is needed to fend off renal and CV competitors.
Dekalb Hybrid Corn Portfolio
Dekalb Hybrid Corn is a Star in Bayer’s BCG matrix, holding a dominant 28% market share in India as of Q4 2025 and delivering double-digit revenue growth with ~22% ROI.
Bayer invested heavily in FY 2024–25 to expand global seed processing capacity, raising capex by about €300 million to meet rising demand for high-yield hybrids.
Projected to become a major cash generator for Crop Science, Dekalb’s high growth and strong margins support scaling R&D and global commercialization through 2026.
Eylea 8mg High-Dose
Eylea 8mg High-Dose has defended Bayer’s ophthalmology share by cutting dosing frequency, helping patient retention and adherence.
It showed mid-single-digit global sales growth in 2025, cushioning Bayer from biosimilar pressure on the 2mg dose.
Leading in the growing AMD and diabetic retinopathy markets, it stays a high-value Star backed by strategic marketing and robust clinical data.
- 2025 growth: ~5–7% global sales rise
- Fewer injections: extends dosing to Q12 weeks
- Offsets 2mg biosimilars
- High margin specialty product
Elinzanetant Menopause Management
Elinzanetant Menopause Management launched in late 2025 in the USA and Europe as a first-in-class non-hormonal therapy for vasomotor symptoms, entering a high-growth menopause market forecasted at ~6–8 billion euros by 2028; analysts project peak sales for Elinzanetant to exceed 1 billion euros.
As a first-to-market innovative product, it needs heavy Bayer support for market access and physician education—estimated launch investment €200–€350M—and, if current uptake holds, is on track to become the Women’s Healthcare segment’s primary revenue driver by 2027.
- Launch: late 2025 (US, EU)
- Type: non-hormonal, first-in-class
- Market size: ~€6–8B by 2028
- Peak sales: >€1B (analyst consensus)
- Estimated launch spend: €200–€350M
- Key year: primary driver by 2027
Bayer’s Blockbusters Surge: Nubeqa €1.5B, Kerendia €1.1B, Elinzanetant >€1B
Bayer Stars: Nubeqa €1.5B (2025), +75% YoY; Kerendia €1.1B, +87% (2025); Dekalb corn 28% India share, ~22% ROI; Eylea 8mg +5–7% (2025); Elinzanetant launch late‑2025, peak >€1B.
| Product | 2025 sales/metric | Growth/notes |
|---|---|---|
| Nubeqa | €1.5B | +75% YoY |
| Kerendia | €1.1B | +87% YoY |
| Dekalb | 28% India | ~22% ROI |
| Eylea 8mg | mid‑single % | Q12 dosing |
| Elinzanetant | launch 2025 | peak >€1B |
What is included in the product
Detailed Word Document
In-depth BCG review of Bayer’s portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest guidance.
Customizable Excel Spreadsheet
One-page Bayer BCG Matrix placing each business unit in a quadrant for swift portfolio decisions
Cash Cows
Xarelto Anticoagulant Portfolio
Despite patent expirations and a 31% sales drop in Q1 2025, Xarelto (rivaroxaban) remains a major cash generator for Bayer, still delivering estimated annual net sales around €3.4 billion in 2024 and funding operations into 2025.
It holds a leading share in the mature anticoagulation market, requires minimal new capex, and its high cash conversion funds R&D for new launches and supports debt service—Bayer reported net debt of €18.9 billion at end-2024.
As the quintessential Cash Cow in Bayer’s BCG matrix, Xarelto provides the liquidity backbone for the company’s turnaround strategy while management milks remaining revenues to preserve margin and free cash flow.
Mirena Contraceptive Family
The Mirena contraceptive family, including Kyleena and Jaydess, stays the market leader in the mature long-acting reversible contraceptive (LARC) segment; in 2025 combined sales grew over 20% year-on-year to roughly €2.6 billion, driven by strong brand loyalty and high gross margins near 80%.
Arize Hybrid Rice
Arize Hybrid Rice holds a 32% share of the organized hybrid rice market in Asia and contributes about 25% of Bayer Crop Science’s regional revenue, with 2024 estimated revenues ~USD 420 million from the brand (here’s the quick math: regional Crop Science revenue ~USD 1.68 billion).
Hybrid rice is a mature, low-capex market for Bayer, so Arize delivers steady gross margins near 38% and strong operating cash flow, funding R&D in digital ag and gene-editing programs.
Consumer Health Dermatology Brands
Bayer’s dermatology category, led by Bepanthen (wound care) and Canesten (antifungal), grew 7% in 2025 within a mature self-care market, driven by stable demand and premium pricing.
These brands hold high consumer trust and top market shares in Europe and Latin America, need maintenance-level investment, and deliver consistent, high-margin cash flows that stabilize Consumer Health results.
The cash generated funds Bayer’s digital transformation and R&D in other consumer segments; here’s the quick math: steady margins converting to predictable free cash flow for reinvestment.
- 7% sales growth in 2025
- High market share in core markets
- Maintenance capex only
- Funds digital/innovation spend
Radiology Contrast Media
Bayer’s Radiology Contrast Media unit, anchored by iodinated Ultravist and gadolinium-based Gadovist, stayed a cash cow in 2025 with ~4% volume growth and ~€1.1bn revenue, reflecting entrenched use in clinical imaging worldwide.
The unit delivered ~25–30% operating margin, low volatility, and predictable free cash flow that funds R&D across Bayer’s life‑science portfolio while consistently hitting internal targets.
- 2025 volume +4%
- Revenue ~€1.1bn
- Op margin 25–30%
- Stable cash flow, low volatility
Bayer’s 2024–25 cash cows: Xarelto, Mirena, Arize, Derm & Radiology fund R&D & debt
Xarelto, Mirena family, Arize hybrid rice, dermatology brands (Bepanthen/Canesten), and Radiology Contrast (Ultravist/Gadovist) are Bayer cash cows in 2024–25, generating recurring high-margin cash (Xarelto ~€3.4bn 2024; Mirena cluster ~€2.6bn 2025; Arize ~USD420m 2024; Radiology ~€1.1bn 2025) that covers maintenance capex and funds R&D and debt (net debt €18.9bn end‑2024).
| Brand/unit | 2024–25 sales | margin/notes |
|---|---|---|
| Xarelto | €3.4bn (2024) | High cash conv.; patent headwinds |
| Mirena family | €2.6bn (2025) | ~80% gross margin |
| Arize | USD420m (2024) | ~38% gross margin |
| Dermatology | — (2025 +7%) | Stable, premium pricing |
| Radiology Contrast | €1.1bn (2025) | Op margin 25–30% |
What You’re Viewing Is Included
Bayer BCG Matrix
The file you're previewing on this page is the final BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, ready-to-use strategic report built for clarity and professional presentation.
Dogs
Glyphosate-Based Herbicides (Roundup)
The legacy Roundup glyphosate portfolio is a Dogs-category cash trap: stagnant sales and a crippling 7.25 billion euro litigation settlement finalized in 2026 have turned it into a low-growth, high-risk asset despite remaining market share.
Bayer faces rising regulatory costs and reputational damage; Group EBIT from crop science fell 12% in 2025, prompting a strategic shift to non-glyphosate alternatives and accelerated R&D spend to exit this segment.
Roundup is now a prime candidate for minimization or divestment as Bayer distances itself from the Monsanto acquisition fallout and reallocates capital to higher-growth seeds and biologics.
Minor Non-Strategic Consumer Brands
Bayer has been divesting minor Consumer Health brands that no longer fit its high-impact self-care focus; in 2024 it sold or discontinued over 20 SKUs, trimming ~€150m in annual sales to boost margins. These Dogs have low market share and face private-label pressure in slow-growth OTC segments, often delivering single-digit revenue growth and negative ROIC. They tie up management time and capital with limited upside, so Dynamic Shared Ownership pushes exit to reallocate resources to core franchises.
Legacy Crop Protection Chemicals
Legacy crop protection chemicals at Bayer generate shrinking margins and low market growth: global sales of conventional actives fell about 6% in 2024 vs 2021, while biologicals grew ~18% annually, eroding pricing power.
Many older molecules face EU restrictions—over 12 active ingredients were delisted or limited since 2019—so Bayer is de-emphasizing these low-return lines.
The group is reallocating R&D and capex toward premium, patent-protected molecules; legacy products are being phased out to raise divisional EBITDA margins, which lagged peers by ~250 basis points in 2024.
Underperforming Nutritionals Category
The Nutritionals segment within Bayer Consumer Health fell over 5% in 2025 sales, reflecting weak demand versus rivals and shifting consumer preferences in a mature market where Bayer holds low market share and misses division growth targets.
Costly turnaround initiatives—budgeted at ~€120–150m in 2025—have not reversed trends, positioning Nutritionals as a candidate for restructuring or divestment to stop diluting division margins and ROIC.
Its underperformance drags an otherwise balanced Consumer Health portfolio, reducing segmental EBITDA margin by an estimated 1.2 percentage points in 2025.
- Sales decline: >5% in 2025
- Turnaround spend: ~€120–150m
- EBITDA drag: ~1.2 pp
- Low market share in mature category
Standard Eylea 2mg Dosage
The original Eylea 2mg has moved into a Dog role as biosimilars and Bayer’s 8mg high-dose siphon off share; U.S. sales for 2mg fell ~38% YoY in 2024 to an estimated $360M as patents expired and market price pressure intensified.
Growth for 2mg is flat-to-negative in the mature ophthalmology market; Bayer has cut promotional spend and is harvesting remaining margins while shifting R&D and commercial focus to higher-margin Star candidates (next-gen Star portfolio launches slated 2025–2027).
- 2024 sales ~ $360M; -38% YoY
- Patent expiries 2023–2024; biosimilar entries 2024
- Marketing redirected to Star launches 2025–2027
- 2mg now managed for residual cash flow, low reinvestment
Bayer's cash-trap “Dogs”: divest/trim Roundup, legacy actives, Nutritionals; harvest Eylea
Bayer’s Dogs (legacy Roundup, older crop actives, low-margin Consumer Health Nutritionals, Eylea 2mg) are low-growth, low-share cash traps: 2024–25 sales down >5–38%, €7.25bn Roundup settlement, ~€150m disposed SKU sales trimmed, Nutritionals drag ~1.2pp EBITDA, Eylea 2mg $360M (2024, -38%).
| Asset | 2024–25 metric | Action |
|---|---|---|
| Roundup | €7.25bn settlement; stagnant sales | Minimize/divest |
| Legacy crop actives | Sales -6% (2021–24) | Phase out |
| Nutritionals | Sales -5% (2025); EBITDA -1.2pp | Restructure/divest |
| Eylea 2mg | $360M 2024; -38% YoY | Harvest cash |
Question Marks
Cell and Gene Therapy Platform
Bayer’s Cell and Gene Therapy (CGT) platform, built via AskBio (acquired 2020) and BlueRock (acquired 2019), sits as a Question Mark: zero current market share but huge upside if trials succeed.
These units burned ~€600–800M in R&D 2023–2024 combined, funding Phase I/II programs with high failure risk; commercialization could multiply value if even one program reaches market.
Turning them into Stars needs strategic patience and continued R&D spend—expect multi-year cash burn and milestone-driven valuation jumps if late-stage success arrives.
Asundexian Stroke Prevention
Asundexian, Bayer’s oral Factor XIa inhibitor in late-stage trials, sits in the Question Mark quadrant because it has near-zero market share but targets the large stroke-prevention market where rivaroxaban (Xarelto) lost exclusivity in 2024; Phase 3 readouts expected 2025–2026 will determine uptake.
If pivotal trials show noninferior bleeding and superior stroke reduction, peak sales could reach $3–6 billion annually by 2032 based on IMS estimates for anticoagulants; otherwise, heavy R&D and commercial spend will be sunk costs against entrenched rivals.
Digital Farming and Climate FieldView
Climate FieldView is a high-growth digital farming platform with single-digit market share versus legacy seed/chemicals; global digital ag revenue hit about $4.6B in 2024 with regenerative tools growing ~18% CAGR, so FieldView sits in Question Marks.
Bayer must invest hundreds of millions in software and data integration—Bayer Digital & Brand spent ≈€300M in 2023—plus partnerships and subsidies to drive farmer adoption and move FieldView into Stars.
Biological Crop Protection Solutions
Bayer is building Biological Crop Protection Solutions and carbon-farming offerings—high-growth niches—though they currently account for under 3% of 2024 EUR 43.5bn group revenue, facing strong startup competition and requiring heavy farmer education and marketing to scale.
If Bayer scales these green solutions, they can move from Question Marks to Stars, potentially capturing share in markets growing at 10–15% CAGR (biologicals) and supporting net-zero goals.
- Biologicals <3% of 2024 revenue
- Sector CAGR ~10–15%
- High customer education cost
- Strong startup competition
Beyonttra for ATTR-CM Cardiology
Beyonttra (acoramidis) targets EU launch 2025/2026 for transthyretin amyloid cardiomyopathy (ATTR-CM); market growth projected ~12–15% CAGR through 2030 and addressable patient count ~50–70k in EU5. As a new entrant it has low initial share versus tafamidis and inotersen, so it’s a Question Mark consuming heavy launch and regulatory spend—estimated €200–€400M early investment—but could deliver high returns if it captures 10–20% market, turning into a Star.
- Launch: EU 2025/2026
- Addressable patients: ~50–70k (EU5)
- Market growth: ~12–15% CAGR to 2030
- Early investment: approx €200–€400M
- Target share to become Star: 10–20%
Bayer’s Question Marks: €1.2–1.5bn R&D, big upside vs low current share
Bayer’s Question Marks (CGT, asundexian, FieldView, biologicals, Beyonttra) have low current share but high upside; combined 2023–24 R&D/commercial spend ~€1.2–1.5bn, potential peak sales per asset $3–6bn (asundexian) or €0.5–1.5bn (Beyonttra); biologicals <3% of €43.5bn 2024 revenue; digital ag market €4.6bn (2024), ~18% regen CAGR.
| Asset | 2024 spend | Peak sales est. | Notes |
|---|---|---|---|
| CGT | €600–800M | €1–5bn | High failure risk |
| Asundexian | €100–200M | $3–6bn | P3 2025–26 |
| FieldView | €300M | €0.5–1.5bn | Digital ag €4.6bn |
| Biologicals | €50–150M | €1–3bn | <3% revenue |
| Beyonttra | €200–400M | €0.5–1.5bn | EU launch 2025–26 |